Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Not Confirmed
Not Confirmed
10-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Industry Trade Show
Not Confirmed
10-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
09 May 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/trading-statement-q1-2025-a-landmark-deal-for-gubamy-1025843
03 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/gubra-welcomes-new-board-members-at-2025-agm-1009921
28 Mar 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/regulatory-condition-satisfied-for-license-agreement-between-abbvie-a-1007210
10 Mar 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/notice-to-convene-annual-general-meeting-2025-997936
03 Mar 2025
// PRESS RELEASE
https://news.abbvie.com/2025-03-03-AbbVie-and-Gubra-Announce-License-Agreement-to-Develop-an-Amylin-Analog-for-the-Treatment-of-Obesity
13 Nov 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/gubras-amylin-obesity-asset-well-tolerated-tied-3-weight-loss-phase-1-trial
ABOUT THIS PAGE